Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma

NCT01474642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Capecitabine/Cisplatin(XP)
DRUG: Capecitabine/Paditaxel(XG)

Sponsor

Samsung Medical Center